Earnings results for MannKind (NASDAQ:MNKD)
MannKind Corporation is expected* to report earnings on 05/12/2021 after market close. The report will be for the fiscal Quarter ending Mar 2021. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.04. The reported EPS for the same quarter last year was $-0.03.
MannKind last issued its earnings results on February 25th, 2021. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.03. The firm had revenue of $18.44 million for the quarter, compared to analyst estimates of $16.13 million. MannKind has generated ($0.27) earnings per share over the last year. MannKind has confirmed that its next quarterly earnings report will be published on Wednesday, May 12th, 2021. MannKind will be holding an earnings conference call on Wednesday, May 12th. Interested parties can register for or listen to the call using this link.
Analyst Opinion on MannKind (NASDAQ:MNKD)
5 Wall Street analysts have issued ratings and price targets for MannKind in the last 12 months. Their average twelve-month price target is $6.63, predicting that the stock has a possible upside of 62.78%. The high price target for MNKD is $8.00 and the low price target for MNKD is $5.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of “Buy.”
MannKind has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $6.63, MannKind has a forecasted upside of 62.8% from its current price of $4.07. MannKind has only been the subject of 3 research reports in the past 90 days.
Dividend Strength: MannKind (NASDAQ:MNKD)
MannKind does not currently pay a dividend. MannKind does not have a long track record of dividend growth.
Insiders buying/selling: MannKind (NASDAQ:MNKD)
In the past three months, MannKind insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $10,140.00 in company stock and sold $0.00 in company stock. Only 1.09% of the stock of MannKind is held by insiders. Only 29.60% of the stock of MannKind is held by institutions.
Earnings and Valuation of MannKind (NASDAQ:MNKD
Earnings for MannKind are expected to grow in the coming year, from ($0.18) to ($0.13) per share. The P/E ratio of MannKind is -19.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of MannKind is -19.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
More latest stories: here